João Paulo Nascimento, Chief Commercial Officer B2C Europe of Towa International, elected president of Equalmed

Barcelona, February 4, 2025. Towa International, -an international pharmaceutical holding company specializing in the research, development, manufacture, marketing and distribution of generic and value-added medicines, which distributes directly in Europe and the United States through its commercial subsidiaries, Towa Pharmaceutical and Breckenridge Pharmaceutical, and in more than 30 countries through its Towa2B business unit, is proud to announce the appointment of João Paulo Nascimento, Chief Commercial Officer B2C Europe of Towa International, representing Towa Pharmaceutical, S.A., as the new President of EQUALMED – Associação Portuguesa de Medicamentos pela Equidade em Saúde for the 2025-2026 biennium.

EQUALMED is a leading pharmaceutical industry entity that advocates for the promotion of generic, biosimilar, and value-added medicines (VAM) as essential tools in enhancing healthcare accessibility.

As the newly appointed president, João emphasizes: “Pharmaceutical policy in both outpatient and hospital markets must continue to promote accessibility while ensuring the sustainability of all industry stakeholders. This will be key to addressing the evolving challenges in the healthcare sector and achieving a balanced, sustainable future.”

This appointment reinforces Towa International’s commitment to equitable access to essential treatments and the development of a more sustainable pharmaceutical sector. Generic, biosimilar, and VAM medicines play a crucial role in ensuring healthcare accessibility for all, and Towa International is proud to be part of an association that is leading these efforts.

Towa International extends its sincere gratitude to the outgoing president, Maria do Carmo Neves, for her invaluable leadership and looks forward to this exciting new chapter.